Belinostat

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Peripheral T-Cell Lymphoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (1)
Peripheral T-Cell Lymphoma
NCT06072131 · Acrotech Biopharma Inc.
2023-10-04 – 2030-11 · Peripheral T Cell Lymphoma
What this study did
Phase 2 (18)
Peripheral T-Cell Lymphoma
NCT00274651 · Valerio Therapeutics
2006-01 – 2009-07 · Cutaneous T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Non-Hodgkin's Lymphoma
What this study did
Other / comorbidity
NCT06406465 · National Cancer Institute (NCI)
2026-11-24 – 2028-07-30 · Carcinoma, Neuroendocrine, Tumor, Neuroendocrine, Tumors, Neuroendocrine, Neuroendocrine; Carcinoma, Small Cell; Receptors
What this study did
NCT05170334 · H. Lee Moffitt Cancer Center and Research Institute
2021-12-15 – 2028-01 · Metastatic Uveal Melanoma
What this study did
NCT04340843 · National Cancer Institute (NCI)
2020-09-08 – 2027-01-27 · Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
What this study did
NCT02737046 · University of Miami
2016-12-12 – 2025-12-31 · Adult T-cell Leukemia-Lymphoma, ATLL
What this study did
NCT02137759 · Emory University
2014-05-07 – 2022-01-24 · Glioblastoma Multiforme of Brain
What this study did
NCT01686165 · University of Arizona
2012-08-31 – 2017-11-09 · Anaplastic Large Cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma
What this study did
NCT00589290 · National Cancer Institute (NCI)
2007-12 – 2014-06 · Thymoma, Thymic Carcinoma
What this study did
NCT00873119 · Valerio Therapeutics
2009-02 – 2012-12 · Carcinoma of Unknown Primary
What this study did
NCT00301756 · National Cancer Institute (NCI)
2006-09 – 2012-12 · Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor, Recurrent Ovarian Carcinoma, Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage III Ovarian Cancer, Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage IV Ovarian Cancer
What this study did
NCT00993616 · National Cancer Institute (NCI)
2009-12 – 2012-07-29 · Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
What this study did
NCT00357162 · National Cancer Institute (NCI)
2006-05 – 2010-12 · de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Secondary Myelodysplastic Syndromes
What this study did
NCT00303953 · National Cancer Institute (NCI)
2006-01 – 2010-08 · Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
What this study did
NCT00357032 · National Cancer Institute (NCI)
2006-05 – 2010-07 · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
What this study did
NCT00365053 · National Cancer Institute (NCI)
2006-06 – 2009-03 · Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
What this study did
NCT00431340 · Valerio Therapeutics
2007-03 – 2007-06 · Multiple Myeloma
What this study did
NCT00131261 · Valerio Therapeutics
2005-01 – 2007-06 · Multiple Myeloma
What this study did
Phase 1/2 (9)
Other / comorbidity
NCT02701673 · M.D. Anderson Cancer Center
2016-06 – 2019-06 · Lymphoma
What this study did
NCT01100944 · National Cancer Institute (NCI)
2010-03-04 – 2015-10-21 · Thymoma, Thymic Carcinoma
What this study did
NCT01310244 · Acrotech Biopharma Inc.
2010-12 – 2015-08 · Stage IV Non-small Cell Lung Cancer
What this study did
NCT00878800 · Valerio Therapeutics
2006-12 – 2012-10 · Dose Escalation: Solid Tumors, MTD: Soft Tissue Sarcomas
What this study did
NCT00321594 · National Cancer Institute (NCI)
2006-05 – 2012-10 · Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
What this study did
NCT00878722 · Valerio Therapeutics
2007-08 – 2012-04 · Acute Myeloid Leukemia
What this study did
NCT01090830 · Holy Cross Hospital, Florida
2010-04 – 2012-02 · Non-Small-Cell Lung Carcinoma
What this study did
NCT01188707 · Herlev Hospital
2010-10-01 – 2011-06-30 · Non Small Cell Lung Cancer
What this study did
NCT00421889 · Valerio Therapeutics
2005-08 – 2009-02 · Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Bladder Cancer
What this study did
Phase 1 (27)
Peripheral T-Cell Lymphoma
NCT07691450 · City of Hope Medical Center
2027-01-03 – 2029-11-24 · Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular Helper T-Cell Lymphoma, Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Recurrent Follicular Helper T-Cell Lymphoma, Follicular-Type, Recurrent Follicular Helper T-Cell Lymphoma, Not Otherwise Specified, Recurrent Hepatosplenic T-Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma, Recurrent Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Follicular Helper T-Cell Lymphoma, Refractory Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Refractory Follicular Helper T-Cell Lymphoma, Follicular-Type, Refractory Follicular Helper T-Cell Lymphoma, Not Otherwise Specified, Refractory Hepatosplenic T-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma, Refractory Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma
What this study did
NCT02142530 · Massachusetts General Hospital
2014-10 – 2018-01 · Non-Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Peripheral T-cell Lymphoma
What this study did
NCT01839097 · Acrotech Biopharma Inc.
2013-05 – 2016-01 · Peripheral T-cell Lymphoma
What this study did
Other / comorbidity
NCT05627245 · National Cancer Institute (NCI)
2023-03-01 – 2027-06-01 · Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Follicular Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Follicular Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
What this study did
NCT05154994 · University of Utah
2022-01-14 – 2026-04-28 · Infiltrating Urothelial Carcinoma, Sarcomatoid Variant, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
What this study did
NCT04315233 · University of Utah
2021-05-03 – 2025-09-25 · Metastatic Breast Cancer, Recurrent Ovarian Carcinoma
What this study did
NCT04315155 · University of Utah
2020-10 – 2025-09 · Metastatic Adenocarcinoma
What this study did
NCT03772925 · National Cancer Institute (NCI)
2019-06-20 – 2025-05-08 · Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
What this study did
NCT04703920 · University of Michigan Rogel Cancer Center
2021-03-04 – 2025-01-02 · Metastatic Breast Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Ovarian Carcinoma, Metastic or Unresectable Pancreatic Adenocarcinoma
What this study did
NCT04184869 · Acrotech Biopharma Inc.
2019-08-05 – 2023-03-31 · Solid Tumor, Hematological Malignancies
What this study did
NCT03432741 · Mayo Clinic
2018-03-27 – 2022-10-03 · Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Breast Carcinoma, Refractory Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Nodal Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Breast Cancer AJCC v6 and v7
What this study did
NCT02680795 · Acrotech Biopharma Inc.
2016-04-27 – 2020-07-21 · Solid Tumors, Hematological Malignancies
What this study did
NCT02875002 · Yale University
2016-10 – 2018-09 · Relapsed and Refractory Aggressive B- and T-cell Lymphomas, Lymphoma
What this study did
NCT02381548 · National Cancer Institute (NCI)
2015-08-18 – 2018-05-23 · Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive, Refractory Acute Myeloid Leukemia, Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive, Secondary Acute Myeloid Leukemia
What this study did
NCT00926640 · National Cancer Institute (NCI)
2009-07-01 – 2018-04-20 · Carcinoma Neuroendocrine, Small Cell Lung Carcinoma, Malignant Epithelial Neoplasms
What this study did
NCT00334789 · National Cancer Institute (NCI)
2006-06-12 – 2018-03-29 · Adult Solid Neoplasm
What this study did
NCT01273155 · National Cancer Institute (NCI)
2011-01-10 – 2017-10-25 · Neoplasms, Lymphomas
What this study did
NCT02679131 · Acrotech Biopharma Inc.
2016-03 – 2017-06 · Relapsed/Refractory Solid Tumors/Hematological Malignancies
What this study did
NCT01317927 · Spectrum Pharmaceuticals, Inc
2010-12 – 2015-06 · Solid Tumor, Hematological Malignancy
What this study did
NCT01583777 · Acrotech Biopharma Inc.
2013-09 – 2015-04 · Advanced Cancer
What this study did
NCT01075425 · Virginia Commonwealth University
2010-05 – 2015-02 · Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia
What this study did
NCT00351975 · National Cancer Institute (NCI)
2006-06 – 2013-03 · Accelerated Phase of Disease, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL, Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Previously Treated Myelodysplastic Syndrome, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Disease, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
What this study did
NCT00413075 · Valerio Therapeutics
2006-06 – 2011-08 · Solid Tumor, Lymphoma
What this study did
NCT00348985 · National Cancer Institute (NCI)
2006-03 – 2010-01 · Adult Grade III Lymphomatoid Granulomatosis, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Primary Central Nervous System Hodgkin Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
What this study did
NCT00413322 · Valerio Therapeutics
2005-09 – 2008-06 · Tumor
What this study did
NCT00354185 · National Cancer Institute (NCI)
2006-05 – 2008-02 · Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Peripheral T-Cell Lymphoma
NCT06561048 · Corvus Pharmaceuticals, Inc.
2024-10-02 – 2028-12 · Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Systemic Anaplastic Large Cell Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell
What this study did
Phase 2 (1)
Other / comorbidity
NCT04747236 · University of Virginia
2021-02-19 – 2030-06-02 · PTCL
What this study did

Competitive landscape

This drug's own stage for Peripheral T-Cell Lymphoma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Belinostat: this drugApprovedSmall moleculeHistone Deacetylase Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Brentuximab VedotinApprovedAntibody–drug conjugateAnti-CD30 antibody-drug conjugatenot yet gradedNo reviewed efficacy summary in this indication
ChidamidePhase 3Small moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
SoquelitinibPhase 3Small moleculeITKnot yet gradedNo reviewed efficacy summary in this indication
Darinaparsin (Darvias)Phase 2Small moleculeapoptosis via reactive oxygen species (ROS) generation and mitochondrial disruptionWeak signalNo reviewed efficacy summary in this indication
Valemetostat Tosylate (Ezharmia)Phase 2Small moleculeEZH1/2not yet gradedNo reviewed efficacy summary in this indication
ZeprumetostatPhase 2Small moleculeEZH1/2not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Belinostat to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
June 2027 (1)
Phase 1Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Follicular Lymphoma …Active not recruiting
Est. primary completion 2027-06-01 · NCT05627245 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Carcinoma, Neuroendocrine, Tumor, Neuroendocrine, Tumors, Neuroendocrine, Neuroendocrine; Carcinoma, Small Cell; ReceptorsRecruiting
Est. primary completion 2027-07-30 · NCT06406465 · CT.gov ↗
What to watch
2029 (1)
November 2029 (1)
Phase 1Peripheral T-Cell LymphomaRecruiting
Est. primary completion 2029-11-24 · NCT07691450 · CT.gov ↗
What to watch
2030 (1)
July 2030 (1)
Phase 3Peripheral T-Cell LymphomaActive not recruiting
Est. primary completion 2030-07 · NCT06072131 · CT.gov ↗
What to watch

See the full readout calendar ↗